News & media

The latest news about Watrium
16 August 2021
Watrium invests in 99x to solve software developer deficit

16 August 2021 – A group of renowned Norwegian technology investors, including Watrium, invests in fast-growing software engineering company 99x to satisfy the growing demand for software developers in Scandinavia and Europe. “There is currently a huge demand and a rapidly growing capacity deficit for software developers in Scandinavia. Investing in growing 99x’s presence is...

13 August 2021
Flexiteek opens new factory in Poland

Watrium’s portfolio company Flexiteek, makers of the world’s leading synthetic teak boat decking ‘Flexiteek 2G’ and marine products, have opened a new factory in Poland. Located in Ostróda, the factory is in the middle of the maritime cluster in Poland, with several OEM boat producers within short driving range. Once in full production, the facility...

13 July 2021
WATRIUM INVESTS IN SENSIO AND PARTNERS WITH LONGSHIP

Watrium invests in Sensio AS together with Sensio’s majority owner Longship. Sensio has recently acquired Safecall Aps, Vestfold Audio, Hospital IT and Roommate As. The proceeds from the placement will be used to support the growth strategy and develop the company. Sensio provides welfare technology primarily in the public sector in Norway, and has started...

28 June 2021
WATRIUM SUPPORTS CMR SURGICAL IN LARGEST EVER MEDTECH FINANCING ROUND

Watrium supports CMR Surgical in largest ever MedTech financing round Watrium supports CMR Surgical in the 600m Series D funding round, the largest ever MedTech private financing round worldwide. The round was led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group and will support the Company’s mission to make keyhole surgery accessible...

05 February 2021
WATRIUM ENABLES DF CAPITAL TO ACCELRATE LOAN BOOK GROWTH

Watrium continues its support of London AIM-listed Distribution Finance Capital Holdings Plc (“DF Capital”) through participation in a GBP 40 million private placement.  DF Capital was recently awarded their banking licence. The net proceeds of the private placement will be utilised to accelerate the Group's business plan and loan book growth by unlocking significant and current pipeline of demand. The additional equity will remove the current GBP 270 million constraint...

29 September 2020
DF Capital granted banking licence

Distribution Finance Capital Holdings plc, a niche lender providing working capital solutions to dealers and manufacturers across the UK, today announces that, following the resubmission of its banking licence application in August 2019, the Company has received confirmation from the Prudential Regulation Authority (PRA) that the PRA, with the consent of the Financial Conduct Authority (FCA), has authorised its...

23 September 2020
Watrium temporarily on the move

While Watrium refurbish its headquarters at Kanalen 5,  Tjuvholmen in Oslo, Norway, the company will temporarily move to its Oslo Atrium office building at Dronning Eufemias gate 6A in Bjørvika in Oslo, from 21 September 2020 to April 2021. Throughout this period, phone number remains the same and business partners should use the following addresses:  ...

Watrium logo
29 June 2020
2019 ANOTHER YEAR WITH SOLID RESULTS

2019 was an eventful year for Watrium, with several exciting new investments, overall strong development for the portfolio companies, attractive and well positioned real estate assets, and moving into 2020 from a position of strength with a robust balance sheet. The continued value creation from a balanced and diversified investment portfolio, is the result of an investment strategy that Watrium has diligently followed for a long time. Notable business milestones in 2019 includes the investments in HitecVision and CMR Surgical, the listings of Ultimovacs and DF Capital, and the...

28 May 2020
Watrium continues backing of Ultimovacs

Watrium continues its support of Oslo-listed Ultimovacs ASA through participation in a NOK 160 million private placement in the pharmaceutical company. Ultimovacs is developing novel immunotherapies against cancer. The net proceeds of the private placement will secure Ultimovacs' funding of its part of the expected project costs in the new randomized phase II trial to...